康哲藥業(00867.HK)與Zydus就創新產品Desidustat簽訂許可協議
格隆匯1月20日丨康哲藥業(00867.HK)公佈，該集團通過其全資附屬公司於2020年1月20日與Cadila Healthcare Limited就其產品Desidustat（ZYAN1）簽訂了許可協議。根據協議的約定，集團通過其全資附屬公司獲得了根據許可技術和Zydus數據在大中華地區（包括中國大陸、香港特別行政區、澳門特別行政區和台灣）開發、註冊、生產、使用與商業化產品的付特許權使用費的、獨家的、可分許可的許可權利，該集團將通過Zydus的技術轉移以實現製劑產品生產在中國的本地化。通過此次合作，該集團現有的產品組合將在產品於區域上市後得以豐富及擴張。
Desidustat是一種創新型口服低氧誘導因子脯氨醯羥化酶抑制劑（HIF-PHI），擬用於治療慢性腎病（CKD）患者的貧血。據報告，中國預估有超過1.2億CKD患者。與現有療法相比，Desidustat採用口服給藥，有望提高患者的治療順應性。Zydus已啟動了兩項DesidustatIII期臨牀試驗。經過6周的治療，與安慰劑相比，在三個Desidustat劑量水平組，主要有效性終點Hb水平的升高均實現了有統計學意義的顯着差異。此外，次要終點Hb反應率在三個Desidustat劑量水平均超過60%。安全性方面，沒有觀察到嚴重不良事件，生命體徵、心電圖參數或安全化驗值均無明顯變化。Desidustat作為新分子實體，已在中國大陸、香港特別行政區、澳門特別行政區和台灣授予物質專利，保護期至2033年12月。
此外，Zydus是一家全球創新制藥公司，從事發現、開發、生產和銷售廣泛的醫療保健療法，這些療法包括小分子藥物、生物製劑和疫苗。Zydus致力於在全球建立更健康的社區，其在全球僱傭了近25,000名員工，其中包括1,400名從事研發的科學家。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
